Incidence of Respiratory Depression and Derivation of a Novel Opioid-Induced Respiratory Depression Risk Prediction Tool

Abstract

Opioid administration can result in respiratory compromise, a serious and sometimes fatal condition. However, it is difficult to identify patients at risk of respiratory depression (RD) on the general care floor (GCF), and cardiorespiratory monitoring practices vary greatly. The purpose of the PRODIGY trial was to quantify the incidence of RD in patients receiving parenteral opioids on the GCF, and to derive a RD risk prediction tool. The study was conducted after IRB approval and in compliance with applicable regulations of participating countries.